Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease

Thank You for Joining Us!

Please complete the following evaluation to claim your credit for the podcast

Question Title

* 1. Please Complete the following

First Name *

Last Name *

Degree *

Email Address *

Pharmacist Only- NABP ID

Pharmacist Only- Date of Birth (MM/DD)

Question Title

* 2. Are you an NLA member?

Yes

No

Not sure

Question Title

* 3. What is your area of specialization?

Cardiology

Family Medicine

General Practice

Internal Medicine

Endocrinology

Other

Question Title

* 4. How long have you been in practice?

<1 year

1-5 years

6-10 years

11-20 years

>20 years

I do not directly provide care

Question Title

* 5. How many patients with dyslipidemia do you currently see each week?

<5

5-15

16-25

26-35

36-45

>45

I do not directly provide care.

Question Title

* 6. Please mark your response to the following questions:
After participating in this activity, I am able to:

	1- Strongly Disagree	2- Disagree	3- Neutral	4- Agree	5- Strongly Agree
Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk.	Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk. 1- Strongly Disagree	Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk. 2- Disagree	Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk. 3- Neutral	Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk. 4- Agree	Describe the role of Lp(a) in ASCVD pathogenesis, its interaction with other lipid molecules, and its contribution to residual cardiovascular risk. 5- Strongly Agree
Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations.	Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations. 1- Strongly Disagree	Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations. 2- Disagree	Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations. 3- Neutral	Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations. 4- Agree	Apply current national and international guidelines for Lp(a) screening, including special considerations for high-risk and underserved populations. 5- Strongly Agree
Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management.	Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management. 1- Strongly Disagree	Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management. 2- Disagree	Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management. 3- Neutral	Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management. 4- Agree	Evaluate emerging data from ongoing clinical trials of Lp(a)- lowering agents and their potential to transform residual risk management. 5- Strongly Agree
Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies.	Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies. 1- Strongly Disagree	Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies. 2- Disagree	Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies. 3- Neutral	Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies. 4- Agree	Integrate Lp(a) measurement into individualized patient risk assessment and prevention strategies. 5- Strongly Agree
Discuss strategies to improve the knowledge, skills or performance of the healthcare team.	Discuss strategies to improve the knowledge, skills or performance of the healthcare team. 1- Strongly Disagree	Discuss strategies to improve the knowledge, skills or performance of the healthcare team. 2- Disagree	Discuss strategies to improve the knowledge, skills or performance of the healthcare team. 3- Neutral	Discuss strategies to improve the knowledge, skills or performance of the healthcare team. 4- Agree	Discuss strategies to improve the knowledge, skills or performance of the healthcare team. 5- Strongly Agree

Question Title

* 7. Please mark your response to the following questions:
Rate your level of agreement with the statement(s) below:

	1- Strongly Disagree	2- Disagree	3- Neutral	4- Agree	5- Strongly Agree
My opportunity for learning assessment was appropriate to the activity.	My opportunity for learning assessment was appropriate to the activity. 1- Strongly Disagree	My opportunity for learning assessment was appropriate to the activity. 2- Disagree	My opportunity for learning assessment was appropriate to the activity. 3- Neutral	My opportunity for learning assessment was appropriate to the activity. 4- Agree	My opportunity for learning assessment was appropriate to the activity. 5- Strongly Agree
The content presented enhanced my current knowledge base.	The content presented enhanced my current knowledge base. 1- Strongly Disagree	The content presented enhanced my current knowledge base. 2- Disagree	The content presented enhanced my current knowledge base. 3- Neutral	The content presented enhanced my current knowledge base. 4- Agree	The content presented enhanced my current knowledge base. 5- Strongly Agree
The content presented was scientifically rigorous and evidence-based.	The content presented was scientifically rigorous and evidence-based. 1- Strongly Disagree	The content presented was scientifically rigorous and evidence-based. 2- Disagree	The content presented was scientifically rigorous and evidence-based. 3- Neutral	The content presented was scientifically rigorous and evidence-based. 4- Agree	The content presented was scientifically rigorous and evidence-based. 5- Strongly Agree
The scope, depth, and level of content were appropriate.	The scope, depth, and level of content were appropriate. 1- Strongly Disagree	The scope, depth, and level of content were appropriate. 2- Disagree	The scope, depth, and level of content were appropriate. 3- Neutral	The scope, depth, and level of content were appropriate. 4- Agree	The scope, depth, and level of content were appropriate. 5- Strongly Agree

Question Title

* 8. Was this activity fair and balanced?

Yes

No

If you answered No, please explain:

Question Title

* 9. Did the activity avoid commercial bias or influence?

Yes

No

If you answered No, please explain:

Question Title

* 10. The faculty provided a disclosure and disclosed any off-label/investigational use of products discussed before the start of the activity.

Yes

No

If you answered No, please explain:

Question Title

* 11. As a result of participating in this activity, what will you do differently to improve the care of your patients?

Question Title

* 12. Select the one option below that most applies with this statement: Based upon my participation in this activity, I:

Gained new strategies, skills or information that I can apply to my area of practice.

Need more information before I can implement new strategies/skills/information into my practice behavior.

Will not change my practice, as my current practice is consistent with information presented.

Will not change my practice, as I do not agree with the information presented.

Question Title

* 13. If you gained new strategies, skills, and/or information that you plan to implement into your practice, what types of changes do you plan to implement?

Question Title

* 14. What barriers do you see to implementing these changes in your practice?

Question Title

* 15. Please provide any additional comments related to the activity in the space below.

Question Title

* 16. Please indicate the type of credit you are claiming

ACCME- Physician

ANCC- Nursing

ACPE- Pharmacy

Participation- All Other